Fat for fostering: Regenerating injured heart using local adipose tissue  by Ma, Hong et al.
EBioMedicine 7 (2016) 25–26
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comCommentaryFat for fostering: Regenerating injured heart using local adipose tissueHong Ma, Jiandong Liu, Li Qian ⁎
Department of Pathology and Laboratory Medicine, McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United StatesDOI of original article: http://dx.doi.org/10.1016/j.ebi
⁎ Corresponding author at: 3340B Medical Bioresearch
Chapel Hill, NC 27599, United States.
E-mail address: li_qian@med.unc.edu (L. Qian).
http://dx.doi.org/10.1016/j.ebiom.2016.03.024
2352-3964/© 2016 The Authors. Published by Elsevier B.Va r t i c l e i n f oArticle history:
Received 16 March 2016
Accepted 16 March 2016
Available online 20 March 2016
chronically formed scar to restore functionality of the damaged
myocardium.
In the current study, Antoni Bayes-Genis et al. conducted the ﬁrst in-
man trial that integrates cardiac adipose tissue derived cell therapy into
tissue engineering for repairing damaged myocardium (Bayes-Genis
et al., 2016). The innovative procedure involves dissection of aIn this issue of EBioMedicine, Bayes-Genis and colleagues (Bayes-Genis
et al., 2016) reported the ﬁrst clinical study investigating safety and
efﬁcacy of the adipose graft transposition procedure (AGTP) in patients
with chronic myocardial infarction undergoing coronary artery bypass
graft (CABG) surgery. This innovative approach takes advantage of the
local existing tissue to repair damaged myocardium, simplifying the
surgical procedure and potentially avoiding the risks of using non-
autologous cells or stem cells that have been manipulated in petri dish.
Myocardial infarction (MI) is a devastating disease condition, and is
one of the leading causes ofmorbidity andmortality inwestern countries.
In the past decade, signiﬁcant advance has been made to develop novel
therapeutic approaches to regenerate infarcted myocardium, including
the stem cell therapy and the most recent reprogramming approaches.
Stem cell therapy currently faces the challenges of poor cell survival,
limited cell–cell interaction and functional integration of engrafted
cells, as well as unclearmechanisms of some beneﬁcial effects observed
in animal model. Clinical studies of using stem cell or stem cell-derived
cardiomyocytes have amixed result (Mummery et al., 2010). The newly
emerged reprogramming approach converting endogenous ﬁbroblasts
into cardiomyocytes could potentially overcome some of these chal-
lenges (Qian and Srivastava, 2013); however, this approach is currently
at its ﬂedgling stage and has been primarily tested on small rodents for
effectiveness and safety. In clinic, revascularization strategies, including
ﬁbrinolysis, percutaneous coronary intervention (PCI), and CABG, have
greatly improved myocardial salvage and prognosis in patients suffer-
ing from acute myocardial infarction. However, patients who miss the
narrow optimal time window for reperfusion therapy or those who
experience detrimental ischemia reperfusion injury during revasculari-
zation, will develop myocardial scar over time, which ultimately
contributes to cardiac dysfunction, malignant arrhythmia, sudden
cardiac death and other major cardiovascular events (Klem et al.,om.2016.03.027.
Building, 111 Mason Farm Rd,
. This is an open access article under2012). Unfortunately, current treatment is unable to replace the
vascularized ﬂap of autologous pericardial adipose tissue to cover
the scar area. Adipose tissue, generally considered as a source of systemic
inﬂammation and risk for cardiovascular diseases, has drawn extensive
attention as an alternative source of multipotent stem cells for healing
infarcted myocardium (Telukuntla et al., 2013; Zuk et al., 2002). Cardiac
adipose tissue is primarily comprised of specially deposited visceral fat
cells around heart supported with local vasculature system. The
same group has discovered a progenitor cell population existing in
human cardiac adipose tissue that has potential to be differentiated
into cardiomyocytes and endothelial cells. Introduction of these
cells ameliorated physical and pathological adverse changes in mu-
rine infarcted hearts (Bayes-Genis et al., 2010). Importantly the re-
sults from APOLLO, ADVANCE, MyStromalCell, and PRECISE trials
proved the safety of adipose tissue-derived stem cell therapy
through intracoronary or intramyocardial delivery (Telukuntla
et al., 2013). However, AGTP procedure using pericardial adipose tis-
sue ﬂap is different in several ways that makes it necessary and im-
portant to evaluate the safety. For example, the ﬂap used in AGTP
contains more heterogeneous cell types and the cardiac adipose tis-
sue is also shown as a risk factor for atherosclerosis, atrial ﬁbrillation,
and ventricular arrhythmia (Iacobellis and Bianco, 2011). As a step
further, preclinical studies using large animals indicated that AGTP
indeed exerted beneﬁcial effects on infarct size, primarily through
promoting angiogenesis in swine models of both acute and chronic
myocardial infarction (Galvez-Monton et al., 2011; Galvez-Monton
et al., 2013).
These promising laboratory ﬁndings and preclinical results
inspired the current prospective, randomized, phase I/II clinical
trial (NCT01473433, AdiFLAP Trial) designed to evaluate the safety
and efﬁcacy of AGTP in patients with chronic myocardial infarction
undergoing CABG. Patients were enrolled if they were CABG candidates
and also with an established chronic myocardial infarction lesion which
wasn't the territory supplied with CABG target vessel(s). The patients
were assessed with late gadolinium enhancement (LGE) MRI to identify
chronic non-revascularization area to guide adipose graft transposition.
The main safety events were deﬁned as arrhythmia, hospital admission
and death during 12-month follow-up. The feasibility endpoints includedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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MRI, biomarkers of cardiac injuries (e.g., troponinI, and NTproBNP),
NYHA class and Framingham derived clinical score.
The AdiFLAP trial included 10 eligible patients who were randomly
divided at 1:1 ratio to receive CABG (control group) or CABG plus AGTP.
One patient in control groupwas dropped out due toMRI claustrophobia.
The AGTP procedures were well tolerated, including 4 inferior and 1
anterior grafts, and did not result in any surgery related complications.
During the 12-month follow-up, none death or hospitalization due to
cardiovascular events was reported in AGTP-treated group. The incidence
of arrhythmias was comparable between control and AGTP-treated
groups. Future studies to further investigate safety on a larger population
and to closelymonitor the adverse cardiovascular events in long termwill
be needed. In spite of the limited sample size and gender bias, ﬁndings in
the current studies suggest that AGTP might be a safe procedure.
In addition, LGE-MRI analysis revealed a−2.16% improvement in
necrosis ratio in AGTP-treated group at 3month,whereas+1.80% dete-
rioration in control group, showing a trend towards attenuating chronic
scar compared to the control group (p= 0.06). However, this trend did
not result in a further improvement at 12month. Similar trendwas also
observed in left ventricular end systolic volume (LVESV) and extracellu-
lar volume (ECV). Unfortunately, no statistically signiﬁcant differences
were identiﬁed in other cardiac function indices, biomarkers, NYHA
class and Framingham-derived clinical score evaluation. Thus a more
detailed segmental analysis is needed in the follow-up studies. It is
worth mentioning that one patient responded unexpectedly well to the
AGTP procedure, whose scar size reduced signiﬁcantly in short term and
long term at one-year follow-up accompaniedwith remarkably improved
heart function. It is intriguing to explore the genetic and cellular bases of
the differential responses from various individuals to AGTP treatment.
Cellular reprogramming techniques coupled with high-throughput
sequencing based omics studies on these patients' samples might
provide clues to the underlying mechanisms and help to discover
bio-markers to deﬁne the AGTP optimal responders for effective
treatment.
Based on the previous animal studies, mechanistically AGTP may
exert its functions through stimulating neovascularization, improving
the local microcirculation and metabolism. Thus, evaluation of the
local neo-angiogenesis and cardiomyocyte metabolism will be helpful
to determine the efﬁcacy of AGTP. The paracrine effects from adipose-
derived progenitor/stem cells might contribute to improving themicro-
environment at the scar site thus enhance themyocardiumcontractility.
Furthermore, if and how AGTP treatment inﬂuences the local inﬂamma-
tory responses aswell as extracellularmatrix degradation, tissue stiffness,
cellularity of the scar area for cytokine/small molecule invasion are all
interesting directions to follow up for detailed mechanistic studies.
Despite the unclear mechanism and the non-signiﬁcant differences
between the control and treatment groups possibly due to its small
number of enrollments, AGTPprocedureholds promise as a novel therapy
in the near future.
Taken together, the results fromcurrent study indicate that AGTP is a
safe treatment option for patients with chronic myocardial infarction. A
larger trial, enrolling patients with a wide arrange of necrotic areas andincluding additional outcome endpoints, shall be performed to further
evaluate the safety and efﬁcacy of AGTP procedure. Nevertheless, utilizing
local adipose tissue might minimize the complications resulted from
introducing exogenous stem cells or stem cell-derived cardiomyocytes;
neither does it introduce any ectopic gene expression or delivery vehicles
such as viruses and DNA constructs used in gene therapy approaches.
Thus local adipose tissue might serve as an important and perhaps
advantageous source for tissue regeneration and disease treatment.
Author contributions
H.M. drafted the commentary, J.L. provided critical comments and
revised the manuscript, L.Q. supervised the writing, revised and ﬁnalized
the manuscript.
Funding source
H.M. and J.L. are supported by NIH/NHLBI R00 HL109079, AHA
15GRNT25530005 to J.L. L.Q. is supported by AHA 13SDG17060010
and the Ellison Medical Foundation (EMF) New Scholar Grant AG-NS-
1064-13 to L.Q.
Conﬂict of interest
None.
References
Bayes-Genis, A., Gastelurrutia, P., Cámara, M.L., et al., 2016. First-in-man safety and efﬁcacy of
the adipose graft transposition procedure (AGTP) in patients with a myocardial scar.
EBioMedicine 7, 248–254.
Mummery, C.L., Davis, R.P., Krieger, J.E., 2010. Challenges in using stem cells for cardiac
repair. Sci. Translat. Med. 2, 27 (ps17).
Qian, L., Srivastava, D., 2013. Direct cardiac reprogramming: from developmental biology
to cardiac regeneration. Circ. Res. 113, 915–921.
Klem, I., Weinsaft, J.W., Bahnson, T.D., Hegland, D., Kim, H.W., Hayes, B., Parker, M.A.,
Judd, R.M., Kim, R.J., 2012. Assessment of myocardial scarring improves risk
stratiﬁcation in patients evaluated for cardiac deﬁbrillator implantation. J. Am.
Coll. Cardiol. 60, 408–420.
Telukuntla, K.S., Suncion, V.Y., Schulman, I.H., Hare, J.M., 2013. The advancing ﬁeld of
cell-based therapy: insights and lessons from clinical trials. J. Am. Heart Assoc. 2,
e000338.
Zuk, P.A., Zhu, M., Ashjian, P., De Ugarte, D.A., Huang, J.I., Mizuno, H., Alfonso, Z.C., Fraser,
J.K., Benhaim, P., Hedrick, M.H., 2002. Human adipose tissue is a source of multipotent
stem cells. Mol. Biol. Cell 13, 4279–4295.
Bayes-Genis, A., Soler-Botija, C., Farre, J., Sepulveda, P., Raya, A., Roura, S., Prat-Vidal, C.,
Galvez-Monton, C., Montero, J.A., Buscher, D., Izpisua Belmonte, J.C., 2010. Human
progenitor cells derived from cardiac adipose tissue ameliorate myocardial infarction
in rodents. J. Mol. Cell. Cardiol. 49, 771–780.
Iacobellis, G., Bianco, A.C., 2011. Epicardial adipose tissue: emerging physiological,
pathophysiological and clinical features. Trends Endocrinol. Metab. 22, 450–457.
Galvez-Monton, C., Prat-Vidal, C., Roura, S., Farre, J., Soler-Botija, C., Llucia-Valldeperas, A.,
Diaz-Guemes, I., Sanchez-Margallo, F.M., Aris, A., Bayes-Genis, A., 2011. Transposition
of a pericardial-derived vascular adipose ﬂap for myocardial salvage after infarct.
Cardiovasc. Res. 91, 659–667.
Galvez-Monton, C., Prat-Vidal, C., Roura, S., Soler-Botija, C., Llucia-Valldeperas, A.,
Diaz-Guemes, I., Sanchez-Margallo, F.M., Bayes-Genis, A., 2013. Post-infarction scar
coverage using a pericardial-derived vascular adipose ﬂap. Pre-clinical results. Int.
J. Cardiol. 166, 469–474.
